MedTrace Logo

Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD)

NCT00299507 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2012-11-28

No results posted yet for this study

Summary

The purpose of this study was to evaluate the effect of the dose concentration and administration frequency of Anecortave Acetate (AA) on visual acuity (VA) and lesion size when administered by posterior juxtascleral depot (PJD) every 3 months (AA 15 mg) or 6 months (AA 15 mg, AA 30 mg) in patients with exudative age-related macular degeneration (AMD).

Conditions

  • Macular Degeneration

Interventions

DRUG

Anecortave Acetate Sterile Suspension, 30 mg/mL

One 0.5 mL posterior juxtascleral depot injection at 3 or 6 month intervals

DRUG

Anecortave Acetate Sterile Suspension, 60 mg/mL

One 0.5 mL posterior juxtascleral depot injection at 6 month intervals

OTHER

Anecortave Acetate Vehicle

One 0.5 mL sham injection at 6 month intervals

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Alcon Investigators · Alcon Research

  • Patricia Zilliox, Ph.D. · Alcon Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2008-04-30
Completion
2008-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00299507 on ClinicalTrials.gov